July 27, 2022
1 min watch
Kitchens J, et al. Personalized treatment interval dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Kitchens reports being a consultant and speaker for Genentech/Roche and that his practice was a clinical study site for the YOSEMITE and RHINE trials.
NEW YORK — In this Healio Video Perspective from the ASRS meeting, John Kitchens, MD, discusses results from the phase 3 YOSEMITE and RHINE trials.
Results showed that treat-and-extend-based personal treatment interval dosing was effective for optimizing faricimab in patients with diabetic macular edema.